The hepatorenal protective effects of silymarin in cancer patients receiving chemotherapy: a randomized, placebo-controlled trial.

BMC Complement Med Ther · 2024 · PMC11375936 · PMID 39232773

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

marginally significantP = 0.059so close (0.05 < p ≤ 0.1)

Mean change of AST over study period was significant in group G3 ( P = 0.01), and marginally significant in group G2 ( P = 0.059).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.